About Us
CRISPRomics®
+
CRISPRomics®
Publications
Pipeline
+
Pipeline®
Expanded Access Policy
News
People
+
Leadership Team
Board of Directors
Careers
Contact
Follow us on Twitter
Find us on LinkedIn
AACR Presentation – New Drugs on the Horizon
April 10, 2022
“KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiency”
© 2023 KSQ Therapeutics, Inc. All rights reserved.